Market Overview

J.P. Morgan Reiterates Neutral Rating on Humana

Share:
Related HUM
A Look At Nvidia's Largest Shareholders And What Their Presence Means
Fast Money Traders Share Their Picks In Health Care Space
Where Is The Democrats' Plan To Fix ObamaCare? (Investor's Business Daily)

In a report published Monday, J.P. Morgan reiterated its Neutral rating on Humana (NYSE: HUM).

J.P. Morgan noted, “Q4 adjusted EPS of $1.19 beats JPMe/consensus $1.05/$1.07 and guidance of $0.98-$1.08 primarily on lower SG&A ($0.11 benefit) and tax rate ($0.08) and with MLR 10 bps above our model on $25m or $0.10 of flu costs and $0.05 of transaction costs. Revenue was $9.56B, slightly below JPMe/consensus of $9.68B/$9.75B. 2013 EPS guidance unchanged despite inclusion of MDF acquisition $0.06, as offset by $0.20 of Q1 flu now baked into #'s. Although retail MLR guidance is up 50 bps (~$0.50 of EPS based on midpoint of rev guidance), the operating earnings guidance for the segment (and also the consolidated SG&A outlook) are unchanged. Open enrollment results in line with expectations, and Med Adv guidance for 2013 reiterated.”

Humana closed on Friday at $75.35.

Latest Ratings for HUM

DateFirmActionFromTo
Apr 2017JefferiesDowngradesBuyHold
Apr 2017Deutsche BankInitiates Coverage OnHold
Mar 2017OppenheimerReinstatesOutperformOutperform

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!